Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab | MicrobiomeTrials
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2022-10-04Est. Completion: 2028-11
Enrollment target: 17 participants
Locations
Lucile Packard Children's Hospital /ID# 240854, Palo Alto, California, United States
Nicklaus Children's Hospital /ID# 241174, Miami, Florida, United States
New York Medical College /ID# 239208, Valhalla, New York, United States
Levine Children's Hospital /ID# 242765, Charlotte, North Carolina, United States
Cincinnati Childrens Hospital Medical Center /ID# 239823, Cincinnati, Ohio, United States
Children's Hospital of Philadelphia - Main /ID# 239294, Philadelphia, Pennsylvania, United States
St Jude Children's Research Hospital /ID# 239184, Memphis, Tennessee, United States
University of Texas Southwestern Medical Center /ID# 240892, Dallas, Texas, United States
Children's Hospital at Westmead /ID# 240091, Westmead, New South Wales, Australia
Royal Children's Hospital /ID# 240384, Parkville, Victoria, Australia
Perth Children'S Hospital /ID# 240382, Perth, Western Australia, Australia